CORT: Begins Ph III Trial of CORLUX for Endogenous Cushing's Syndrome

Ridgeland, MS, DEC 19, 2007 (EventX/Knobias.com via COMTEX) -- CORT | charts | news | PowerRating -- By Fain Hughes, fhughes@knobias.com

Corcept Therapeutics Incorporated (CORT) announced the commencement of its Phase 3 trial with CORLUX for the treatment of endogenous Cushing's Syndrome. CORLUX is a cortisol receptor (GR-II) antagonist. The FDA indicated that a single study may provide a reasonable basis for the submission of a New Drug Application. Corcept previously received Orphan Drug Designation for CORLUX for the treatment of endogenous Cushing's Syndrome.

Cushing's Syndrome is caused by prolonged exposure of the body's tissues to high levels of the hormone cortisol. Cushing's Syndrome is relatively rare and most commonly affects adults aged 20 to 50. Symptoms vary, but most people have one or more of the following manifestations: High blood sugar, high blood pressure, upper body obesity, rounded face, increased fat around the neck, thinning arms and legs, severe fatigue and weak muscles. Irritability, anxiety, cognitive disturbances and depression are common. Cushing's Syndrome can affect every organ system in the body and can be lethal if not treated effectively.

KNOBIAS DISCLAIMER: All statements made in this article were made by the Company and do not in any way reflect the opinions of Knobias. Knobias is not a registered broker-dealer, nor investment advisor, and does not endorse or recommend any securities mentioned. This story is provided for informational purposes only and is not intended for trading purposes. Knobias shall not be liable for any actions taken in reliance of any information provided herein. Republication or redistribution of Knobias content is expressly prohibited without prior written consent of Knobias.com, LLC.

ABOUT KNOBIAS: Knobias is a premier financial information provider of trading and investing data covering all U.S. equities for investors and security professionals. Knobias is best described by its three major components: Real-time desktop applications providing quotes, charts, level 2, analysis etc.; Knobias RAiDAR providing thousands of real-time news stories, alerts and documents daily; Knobias fundamentals providing a comprehensive database of fundamental research information.

If your company wishes to participate in the EventX newswire, please contact Knobias: http://www.knobias.com

Knobias.com, LLC 601-978-3399 601-978-3675 info@knobias.com www.knobias.com/cmtx

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index